Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG. Ghobrial IM, et al. Among authors: roccaro a. Clin Cancer Res. 2010 Feb 1;16(3):1033-41. doi: 10.1158/1078-0432.CCR-09-1837. Epub 2010 Jan 26. Clin Cancer Res. 2010. PMID: 20103671 Free PMC article. Clinical Trial.
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC. Yasui H, et al. Blood. 2005 Jul 15;106(2):706-12. doi: 10.1182/blood-2005-02-0838. Epub 2005 Mar 31. Blood. 2005. PMID: 15802527 Free PMC article.
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC. Ishitsuka K, et al. Blood. 2005 Sep 1;106(5):1794-800. doi: 10.1182/blood-2005-01-0346. Epub 2005 May 3. Blood. 2005. PMID: 15870175 Free PMC article.
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC. Yasui H, et al. Cancer Res. 2005 Aug 15;65(16):7478-84. doi: 10.1158/0008-5472.CAN-05-0850. Cancer Res. 2005. PMID: 16103102
Bortezomib as an antitumor agent.
Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC. Roccaro AM, et al. Curr Pharm Biotechnol. 2006 Dec;7(6):441-8. doi: 10.2174/138920106779116865. Curr Pharm Biotechnol. 2006. PMID: 17168660 Review.
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P. Ghobrial J, et al. Among authors: roccaro a. Oncology (Williston Park). 2007 Jun;21(7):785-92; discussion 798-800. Oncology (Williston Park). 2007. PMID: 17722741 Free article. Review.
198 results